SNSS interim Phase 3 VALOR analysis due September. DYAX discontinues Phase 2 ecallantide. AEGR prices offering.
Dyax Corp. (NASDAQ: DYAX) announced that it will discontinue its Phase 2 trial of ecallantide in the acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema following an interim analysis showing it not to be statistically effective.
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) said that it expects interim analysis of its Phase 3 VALOR trial of vosaroxin, in patients with first relapsed or refractory acute myeloid leukemia (AML), to be completed during September 2012.
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) priced its underwritten public offering of 3.4m shares at a price to the public of $14.75 per share, for net proceeds of approximately $47.3m.